证券代码：688317 证券简称：之江生物 公告编号：2026-006 上海之江生物科技股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海之江生物科技股份有限公司（以下简称"公司"或"之江生物"）于 2026 年 2 月 24 日召开第五届董事会第十八次会议，审议通过了《关于 2026 年 度日常关联交易预计的议案》。该议案关联董事邵俊斌先生及倪卫琴女士对部分 关联交易进行了回避表决。出席会议的非关联董事一致同意该议案。 独立董事专门会议审议通过该议案，并形成以下意见：公司对 2026 年度日 常关联交易的预计符合正常的业务发展需要，定价符合市场化原则，符合公司和 全体股东的利益，对公司独立性无影响，不存在损害公司及股东利益的情况，同 意将《关于 2026 年度日常关联交易预计的议案》提交董事会审议。 （二）本次日常关联交易预计金额和类别 单位：万元 | 关联人 ...

重要内容提示： 投资种类：安全性高、满足保本要求、流动性好、产品期限不超过 12 个月的产品（包括但不限于购买保本型理财产品、结构性存款、大额存单、定期 存款、通知存款、协定存款等）。 投资金额：不超过人民币 8.6 亿元（含 8.6 亿元）。 证券代码：688317 证券简称：之江生物 公告编号：2026-007 上海之江生物科技股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 已履行及拟履行的审议程序：上海之江生物科技股份有限公司（以下简 称"公司"或"之江生物"）于 2026 年 2 月 24 日召开第五届董事会第十八次会 议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，该事 项在董事会审批权限范围内，无需提交股东会审批。保荐机构国泰海通证券股份 有限公司（以下简称"保荐人"）对上述事项出具了明确同意的核查意见。 特别风险提示：尽管公司拟投资安全性高、满足保本要求、流动性好的 投资产品，但金融市场受宏观经济影响较大，公司将根据经济形势以及金融市场 的变 ...

Regulatory Updates - The National Medical Products Administration (NMPA) has released the "Guidelines for Pharmaceutical Research on Chemical Drugs for Rare Diseases (Trial)" to enhance support for rare disease drug development and improve technical guidance principles [1] - Hengrui Medicine's innovative drug SHR-1918 injection has been accepted for priority review by the NMPA, aimed at treating patients with homozygous familial hypercholesterolemia [1] - CanSino Biologics has expanded the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, which is expected to positively impact the company's performance [2] - Tongrentang Pharmaceutical has received product registration approval from Health Canada for several products, including children's cough syrup, although further administrative approvals are required for sales [3] - Shanghai Pharmaceuticals has obtained a drug registration certificate in Singapore for rivaroxaban tablets, which are used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients [4] - Baotai has received acceptance for the marketing authorization application of its drug BAT4406F, intended for treating adult patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder [5] Industry Developments - Zhejiang Medicine plans to invest 250 million yuan in a silver economy fund in collaboration with a private equity fund, focusing on the healthcare sector [6] - Zhijiang Biology has completed a strategic increase in its stake in Sanyou Biopharmaceuticals, enhancing its position in the precision medicine sector [7] - Xianweida Biopharmaceutical has entered a commercialization agreement with Pfizer China for its GLP-1 receptor agonist, which could yield up to $495 million in payments [8] Financial Performance - Sangfor Technologies reported a projected net profit increase of 317.09% for 2025, driven by a significant collaboration with Pfizer that resulted in a revenue recognition of approximately 2.89 billion yuan [9] Capital Market Activities - Duorui Pharmaceuticals announced a stock suspension following the expiration of a tender offer period, pending confirmation of the offer results [10] - Jiutian Pharmaceutical completed a share buyback of 1.24% of its total shares, with a total transaction amount of 100 million yuan [11] - Shenlian Biopharmaceutical plans to acquire controlling interest in Shiziyuan Biotechnology for 237 million yuan, aiming to expand into innovative drug business [12]

Core Viewpoint - Zhijiang Biotech has completed a strategic increase in its stake in Sanyou Biopharmaceutical Co., Ltd., emphasizing the importance of technological complementarity and industrial synergy in the biopharmaceutical sector [1] Group 1: Company Actions - The strategic increase in stake aims to further integrate advantageous resources and solidify Zhijiang Biotech's position in the full industry chain of precision medicine, focusing on "diagnosis + treatment" [1] - The financing round also attracted interest from Shenzhen Yanghe Investment Pharmaceutical Industry Investment Co., Ltd., a professional investment platform under Zhuhai Gree Group, which participated in the strategic investment in Sanyou Biopharmaceutical [1]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Core Viewpoint - The company is focusing on enhancing its research and innovation efforts while also prioritizing external growth opportunities through mergers, acquisitions, and strategic partnerships to expand its business scope and develop a second growth curve [1] Group 1: Research and Innovation - The company is continuously increasing its investment in research and innovation [1] - There is a strategic shift from diagnostics to a full industry chain layout that includes both "diagnostics + treatment" [1] Group 2: Business Expansion - The company aims to steadily expand its business areas through mergers, equity participation, and strategic collaborations [1] - The focus is on cultivating a second growth curve to promote high-quality and sustainable development [1] Group 3: Financial Management - The company is exercising caution in its financial management to enhance long-term value [1] - There is a commitment to returning value to investors who have placed their trust in the company [1]

Group 1 - The company, Shanghai Zhijiang Biological Technology Co., Ltd., has approved a share repurchase plan to buy back shares using its own funds and a special loan for stock repurchase, with a maximum price of RMB 37.99 per share and a total repurchase amount between RMB 60 million and RMB 120 million [2][4] - The repurchase period is set for 12 months from the date of board approval, which was on October 15, 2025 [2][4] Group 2 - As of January 2026, the company has repurchased a total of 1,940,434 shares, representing 1.01% of the current total share capital of 192,157,999 shares, with a total expenditure of RMB 41,869,022.21 [3] - The highest and lowest prices for the repurchased shares were RMB 23.49 and RMB 19.58 per share, respectively [3]

Group 1 - The core point of the article is that Zhijiang Bio announced a share buyback, having repurchased a total of 1,940,434 shares through the Shanghai Stock Exchange trading system as of January 30, 2026 [1] Group 2 - The share buyback was conducted via centralized bidding [1] - The announcement was made on February 2 [1]

Summary of Key Points Core Viewpoint - Zhijiang Biology (688317.SH) has announced a share buyback program, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,940,434 shares, which represents 1.01% of its current total share capital [1] - Compared to the previous disclosure, the repurchased shares have increased by 0.07% [1] - The highest price paid for the repurchased shares was 23.49 CNY per share, while the lowest price was 19.58 CNY per share [1] Group 2: Financial Implications - The total amount spent on the share buyback was 41,869,022.21 CNY, excluding transaction fees such as stamp duty and commissions [1]

证券代码：688317 证券简称：之江生物 公告编号：2026-005 上海之江生物科技股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，回购股份占上市公司总股本的 比例每增加 1%的，应当在事实发生之日起 3 个交易日内予以披露；在每个月的前 3 个交易日内公告截至上月末的回购进展情况。现将公司回购股份进展情况公告如 下： 公司 2026 年 1 月，公司通过上海证券交易所交易系统以集中竞价交易方式累 计回购公司股份 127,500 股，占公司当前总股本 192,157,999 股的比例为 0.07%， 回购成交的最高价为 23.49 元/股，最低价为 20.39 元/股，支付的资金总额为人 民币 2,738,814.62 元（不含印花税、交易佣金等交易费用）。 关于 2025 年第三次以集中竞价交易方式回购公司股份 比例达到总股本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2 ...